Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
26 studies found for:    pomalidomide | Open Studies | multiple myeloma | Phase 2
Show Display Options
Rank Status Study
1 Recruiting Pomalidomide in Combination With Low-dose Dexamethasone or Pomalidomide in Combination With Low-dose Dexamethasone and Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Following Lenalidomide-based Therapy in the First or Second Line Setting
Condition: Multiple Myeloma
Interventions: Drug: Pomalidomide;   Drug: Dexamethasone;   Drug: Daratumumab
2 Recruiting Pomalidomide in Relapsed and Refractory Multiple Myeloma (RRMM)
Condition: Multiple Myeloma
Interventions: Drug: Pomalidomide;   Drug: Dexamethasone;   Drug: Cyclophosphamide
3 Recruiting A Study of Elotuzumab With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Elotuzumab;   Drug: Pomalidomide;   Drug: Bortezomib;   Drug: Dexamethasone
4 Recruiting Study of Pomalidomide, Cyclophosphamide, Dexamethasone in Relapsed/Refractory Multiple Myeloma
Conditions: Multiple Myeloma in Relapse;   Multiple Myeloma, Refractory
Interventions: Drug: Pomalidomide;   Drug: Cyclophosphamide;   Drug: Dexamethasone
5 Recruiting Trial of Pomalidomide and Low-dose Dexamethasone With or Without Elotuzumab to Treat Refractory and Relapsed and Refractory Multiple Myeloma (ELOQUENT-3)
Condition: Multiple Myeloma
Interventions: Drug: Elotuzumab;   Drug: Pomalidomide;   Drug: Dexamethasone
6 Recruiting A Multicenter Open Label Phase II Study of Pomalidomide and Cyclophosphamide and Dexamethasone in Relapse/Refractory Multiple Myeloma Patients Who Were First Treated Within the IFM/DFCI 2009 Trial
Conditions: Multiple Myeloma;   First Relapse
Interventions: Drug: PCD;   Procedure: Autologous transplantation (ASCT)
7 Recruiting A Study of Elotuzumab in Combination With Pomalidomide and Low Dose Dexamethasone (EPd) in Patients With Multiple Myeloma Relapsed or Refractory to Prior Treatment With Lenalidomide
Condition: Multiple Myeloma
Interventions: Drug: Elotuzumab;   Drug: Pomalidomide;   Drug: Dexamethasone
8 Recruiting Pomalidomide for Lenalidomide for Failures
Condition: Multiple Myeloma
Interventions: Drug: POM;   Drug: Steroids;   Drug: PLD;   Drug: CFZ;   Drug: BTZ;   Drug: CLA;   Drug: Other drugs
9 Recruiting UARK 2015-03 A Phase II Trial of a Novel Proteasome/IMiD Combination
Condition: Multiple Myeloma
Interventions: Drug: Ixazomib;   Drug: Pomalidomide;   Drug: Dexamethasone
10 Recruiting Filanesib (ARRY-520) in Combination With Pomalidomide and Dexamethasone for Relapsed/Refractory (R/R) Multiple Myeloma (MM) Patients
Condition: Multiple Myeloma
Intervention: Drug: Filanesib, pomalidomide and dexamethasone
11 Recruiting Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: pomalidomide;   Drug: carfilzomib;   Drug: dexamethasone
12 Recruiting Efficacy and Toxicity Study of Pomalidomide and Dexamethasone in Patients Who Have Relapsed After Exposure to Lenalidomide and Bortezomib
Conditions: Multiple Myeloma;   Relapse After Use of Lenalidomide and Bortezomib
Intervention: Drug: Pomalidomide and Dexamethasone
13 Recruiting Pomalidomide and Dexamethasone With or Without Ixazomib in Treating Patients With Refractory Multiple Myeloma
Condition: Multiple Myeloma in Relapse
Interventions: Drug: pomalidomide;   Drug: ixazomib;   Drug: dexamethasone
14 Recruiting Study of Pomalidomide, Dexamethasone, and Romidepsin for Rel/Ref Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Romidepsin;   Drug: pomalidomide;   Drug: Dexamethasone
15 Recruiting SL-401 in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: SL-401/ Pomalidomide/ Dexamethasone
16 Recruiting A Safety and Efficacy Study of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Carfilzomib;   Drug: Pomalidomide;   Drug: Dexamethasone
17 Recruiting Study of Pomalidomide and Dexamethasone With Growth Factor Support in Patients With Relapsed/Refractory Multiple Myeloma
Condition: Myeloma
Interventions: Drug: Pomalidomide;   Drug: Dexamethasone;   Drug: G-CSF;   Behavioral: Phone Calls
18 Recruiting Study of Ibrutinib in Combination With Pomalidomide and Dexamethasone in Subjects With Relapsed/Refractory Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Ibrutinib;   Drug: Pomalidomide;   Drug: Dexamethasone;   Drug: Placebo
19 Recruiting Pomalidomide, Ixazomib Citrate, and Dexamethasone in Treating Patients With Previously Treated Multiple Myeloma With Extramedullary Disease or Plasma Cell Leukemia
Conditions: Plasma Cell Leukemia;   Plasma Cell Myeloma;   Plasmacytoma
Interventions: Drug: Dexamethasone;   Drug: Ixazomib Citrate;   Other: Laboratory Biomarker Analysis;   Drug: Pomalidomide
20 Recruiting Ixazomib With Pomalidomide, Clarithromycin and Dexamethasone in Treating Patients With Multiple Myeloma
Condition: Myeloma
Interventions: Drug: Clarithromycin;   Drug: Dexamethasone;   Drug: Ixazomib Citrate;   Drug: Pomalidomide

   Previous Page Studies Shown (1-20) Next Page (21-26) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.